title: [Chemotherapy in Patients Complicated with Interstitial Pneumonia].
abstract: Interstitial pneumonia has high risk for chemotherapy-related exacerbation. Chemotherapy-related exacerbation is often fatal with respiratory failure. When we treat the cancer patient with interstitial pneumonia, it is necessary for us to regard of the efficacy of chemotherapy, and the frequency and mortality of chemotherapy-related exacerbation. All anti-cancer drugs has the possibilities of chemotherapy-related exacerbation. The incidence of chemotherapy-related exacerbation was higher in patients with target therapy agent or immune-checkpoint therapy agent, though there is not an interstitial pneumonia patient. In patients complicated with interstitial pneumonia, you should not use of these drugs, such as target therapy agent or immune-checkpoint therapy agent.
authors.affiliation: Dept. of Thoracic oncology, Kanagawa Cancer Center.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Sata
authors.forename: Terufumi
authors.initials: T
authors.lastname: Kato
mesh_terms: D000969:Antinematodal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000150:complications* / Q000175:diagnosis; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D000969:Antinematodal Agents